SUMMARY OF SAFETY AND EFFECTIVENESS NIDEK INCORPORATED OPD-STATION SOFTWARE

SUBMITTER INFORMATION

A. Company Name:

Nidek Incorporated

B. Company Address:

47651 Westinghouse Drive.

Fremont, CA 94539-7474

C. Company Phone:

(510) 353-7719

Company Fax:

(510) 226-5750

D. Contact Person:

Mr. Hiro Matsuzaki

Regulatory and QA Manager

Nidek Incorporated

E. Date Summary Prepared:

August 22, 2005

DEVICE IDENTIFICATION

A. Generic Device Name:

Ophthalmic, aberrometer

Topographer, corneal, ac-powered

B. Trade/Proprietary Name:

OPD-Station software

C. Classification:

Class I 886.1760

D. Product Code:

NCF, MMQ

SUBSTANTIAL EQUIVALENCE

The Nidek Incorporated OPD-Station software is of comparable type and is substantially equivalent to the following predicate devices:

Predicate Device	Manufacturer	510(k) No.	Date Cleared
Topographic Modeling System	Computed Anatomy	K944207	Dec. 7, 1994
Nidek OPD-Scan	Nidek Co. Ltd.	K003299	March 9, 2001

DEVICE DESCRIPTION

Nidek has developed a stand-alone software option for users of the OPD-ScanTM device called OPD-Station, which will run on an independent PC (i.e., separate from the OPD-ScanTM device). The OPD-Station software is able to access data measured by the OPD-ScanTM device via a separate Nidek data management software package called NAVIS.

The OPD-Station uses the same software as that used for the OPD-Scan device so that a physician can view OPD-Scan data on their PC of choice. However, the OPD-Station software has the following new functions:

- Maps of Point Spread Function (PSF), Modulation Transfer Function (MTF), MTF graphing, and Visual Acuity mapping
- Improved color mapping

INTENDED USE

The OPD-Station software is indicated for use in analyzing the corneal shape and refractive powers measured by the OPD-Scan Models ARK-9000 or ARK-10000, and to display the data in the form of maps, and manage the data.

TECHNOLOGICAL CHARACTERISTICS

A comparison of the technological characteristics of the OPD-Station software and the predicate devices has been performed, and the results of this comparison demonstrate that the OPD-Station software is equivalent to the marketed predicate devices

PERFORMANCE DATA

The performance data indicate that the OPD-Station software meets all specified requirements, and is substantially equivalent to the predicate devices.



AUG 2 4 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Nidek Co., Ltd. % Ms. Carol L. Patterson, President Patterson Consulting Group, Inc. 21911 Erie Lane Lake Forest, CA 92630

Re: K050336

Trade/Device Name: OPD-Station Software Regulation Number: 21 CFR 886.1760 Regulation Name: Ophthalmic Refractometer

Regulatory Class: Class I Product Code: NCF, MMQ

Dated: July 15, 2005 Received: July 18, 2005

Dear Ms. Patterson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 827-8910. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

David M. Whipple

Acting Director

Division of Ophthalmic and Ear,

Nose and Throat Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number:	K050336	(To Be Assigned By FDA)	
Device Trade Name:	OPD-Station Softwa	re	
Indications For Use:	The OPD-Station software is indicated for use in analyzing the corneal shape and refractive powers measured by the OPD-Scan Models ARK-9000 or ARK-10000, and to display the data in the form of maps, and manage the data.		
Prescription Use X (Part 21 CFR 801 Subpart	AND/OR	Over-The-Counter Use (21 CFR 807 Subpart C)	
_	•	E-CONTINUE ON ANOTHER PAGE	
D N 5	Ohylsion Sign-Off) ivision of Ophthalmic Earlose and Throat Devises 10(k) Number		

01/31/05

Page 1 of __1__